Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners : the Perseo study
BACKGROUND: The link between infection with hepatitis C virus (HCV) and personality disorders (PD) has not been investigated in detail. The aim of this study was to compare the effectiveness of HCV treatment in prisoners with and without PD.
METHODS: We performed a prospective multicentre study in inmates from 25 Spanish prisons who had been treated with pegylated interferon alfa-2a plus ribavirin in 2011. PD diagnosis was based on the Personality Diagnostic Questionnaire-4+. We calculated adjusted Odds Ratios (AOR) and 95 % confidence intervals (95 % CI) using logistic regression.
RESULTS: The sample included 236 patients (mean age: 40.3 years, 92.8 % male, 79.2 % intravenous drug users, and 26.3 % HIV-coinfected). The prevalence of PD was 72.5 %. 32.2 % of patients discontinued treatment; this percentage was higher in patients with HCV genotypes 1/4 (AOR = 3.55; CI:1.76-7.18) and those without PD (AOR = 2.51; 1.23-5.11). Treatment discontinuation was mainly for penitentiary reasons (40.3 %): release or transfer between prisons. The rate of sustained viral response (SVR) was 52.1 % by ITT and 76.9 % by observed treatment (OT). SVR was higher among patients with genotype 2 or 3, and those with low baseline HCV-RNA. We did not observe any differences between individuals with and without PD in term of SVR, HCV genotype or HIV infection.
CONCLUSIONS: Our results support the safety and clinical effectiveness of the treatment of chronic HCV infection in correctional facilities, both in prisoners with PD and those without. Our data support non-discrimination between patients with and without PD when offering treatment for HCV infection to prison inmates.
TRIAL REGISTRATION: Trial registration number (TRN) NCT01900886 . Date of registration: July 8, 2013.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 15(2015) vom: 19. Aug., Seite 355 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marco, Andrés [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3WJQ0SDW1A |
|---|
| Anmerkungen: |
Date Completed 09.03.2016 Date Revised 02.12.2018 published: Electronic ClinicalTrials.gov: NCT01900886 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-015-1102-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251959694 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251959694 | ||
| 003 | DE-627 | ||
| 005 | 20231224163118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-015-1102-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0839.xml |
| 035 | |a (DE-627)NLM251959694 | ||
| 035 | |a (NLM)26286450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marco, Andrés |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners |b the Perseo study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01900886 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The link between infection with hepatitis C virus (HCV) and personality disorders (PD) has not been investigated in detail. The aim of this study was to compare the effectiveness of HCV treatment in prisoners with and without PD | ||
| 520 | |a METHODS: We performed a prospective multicentre study in inmates from 25 Spanish prisons who had been treated with pegylated interferon alfa-2a plus ribavirin in 2011. PD diagnosis was based on the Personality Diagnostic Questionnaire-4+. We calculated adjusted Odds Ratios (AOR) and 95 % confidence intervals (95 % CI) using logistic regression | ||
| 520 | |a RESULTS: The sample included 236 patients (mean age: 40.3 years, 92.8 % male, 79.2 % intravenous drug users, and 26.3 % HIV-coinfected). The prevalence of PD was 72.5 %. 32.2 % of patients discontinued treatment; this percentage was higher in patients with HCV genotypes 1/4 (AOR = 3.55; CI:1.76-7.18) and those without PD (AOR = 2.51; 1.23-5.11). Treatment discontinuation was mainly for penitentiary reasons (40.3 %): release or transfer between prisons. The rate of sustained viral response (SVR) was 52.1 % by ITT and 76.9 % by observed treatment (OT). SVR was higher among patients with genotype 2 or 3, and those with low baseline HCV-RNA. We did not observe any differences between individuals with and without PD in term of SVR, HCV genotype or HIV infection | ||
| 520 | |a CONCLUSIONS: Our results support the safety and clinical effectiveness of the treatment of chronic HCV infection in correctional facilities, both in prisoners with PD and those without. Our data support non-discrimination between patients with and without PD when offering treatment for HCV infection to prison inmates | ||
| 520 | |a TRIAL REGISTRATION: Trial registration number (TRN) NCT01900886 . Date of registration: July 8, 2013 | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Antón, José J |e verfasserin |4 aut | |
| 700 | 1 | |a Trujols, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Saíz de la Hoya, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a de Juan, José |e verfasserin |4 aut | |
| 700 | 1 | |a Faraco, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Caylà, Joan A |e verfasserin |4 aut | |
| 700 | 0 | |a Perseo Group |e verfasserin |4 aut | |
| 700 | 1 | |a Alia, C |e investigator |4 oth | |
| 700 | 1 | |a Amaya, F |e investigator |4 oth | |
| 700 | 1 | |a Antolin, J M |e investigator |4 oth | |
| 700 | 1 | |a Borrego, J |e investigator |4 oth | |
| 700 | 1 | |a Campo, E |e investigator |4 oth | |
| 700 | 1 | |a da Silva, A |e investigator |4 oth | |
| 700 | 1 | |a Díaz, J R |e investigator |4 oth | |
| 700 | 1 | |a Domingo, J |e investigator |4 oth | |
| 700 | 1 | |a Gallego, C |e investigator |4 oth | |
| 700 | 1 | |a García-Guerrero, J |e investigator |4 oth | |
| 700 | 1 | |a Herrero, A M |e investigator |4 oth | |
| 700 | 1 | |a Jiménez-Galan, G |e investigator |4 oth | |
| 700 | 1 | |a Laine, J M |e investigator |4 oth | |
| 700 | 1 | |a Leandro, E |e investigator |4 oth | |
| 700 | 1 | |a López, C |e investigator |4 oth | |
| 700 | 1 | |a Muros, R |e investigator |4 oth | |
| 700 | 1 | |a Paniagua, F |e investigator |4 oth | |
| 700 | 1 | |a Pérez de los Cobos, J |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Valenzuela, A |e investigator |4 oth | |
| 700 | 1 | |a Planella, R |e investigator |4 oth | |
| 700 | 1 | |a Pozo, E |e investigator |4 oth | |
| 700 | 1 | |a Rebolledo, J R |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Arrobas, P |e investigator |4 oth | |
| 700 | 1 | |a Sarriera, C |e investigator |4 oth | |
| 700 | 1 | |a Solé, C |e investigator |4 oth | |
| 700 | 1 | |a Vasallo, L C |e investigator |4 oth | |
| 700 | 1 | |a Veiras, M |e investigator |4 oth | |
| 700 | 1 | |a Yllobre, C |e investigator |4 oth | |
| 700 | 1 | |a Zúñiga, J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 15(2015) vom: 19. Aug., Seite 355 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g day:19 |g month:08 |g pages:355 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-015-1102-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2015 |b 19 |c 08 |h 355 | ||